Platelet activation and thromboxane A2 formation pathway

The platelet activation and thromboxane A2 (TXA2) formation pathway is a central mechanism in hemostasis and the development of arterial thrombosis [StatPearls]. Following platelet stimulation by agonists such as collagen or thrombin, arachidonic acid is liberated from the cell membrane and converted into TXA2 via the sequential actions of cyclooxygenase-1 (COX-1) and thromboxane synthase [PubMed: 25994039]. TXA2 serves as a powerful autocrine and paracrine mediator that binds to the G protein-coupled thromboxane receptor (TP), triggering further platelet aggregation and potent vasoconstriction [UniProt]. This pathway is the primary target for aspirin, which irreversibly inhibits COX-1 to reduce TXA2 production and lower the risk of cardiovascular events [NIH]. Excessive activation of this pathway is a key driver of myocardial infarction and stroke, while its inhibition is a cornerstone of secondary prevention in cardiovascular medicine [Nature Reviews Cardiology]. Pharmacological modulation of this cascade remains a standard of care in managing atherothrombotic diseases [PubMed].

Other names

Thromboxane A2 signaling pathwayTXA2 synthesis and signalingPlatelet aggregation pathwayCOX-1/TXA2 pathway

Drugs targeting this pathway primarily work by irreversibly inhibiting the cyclooxygenase-1 (COX-1) enzyme, thereby preventing the conversion of arachidonic acid into prostaglandin H2, the precursor to thromboxane A2 [StatPearls]. Other agents may act as thromboxane synthase inhibitors or as antagonists of the thromboxane A2 (TP) receptor to block the downstream effects of TXA2 on platelet aggregation and vascular tone [PubMed: 11007114].